Elite Pharmaceuticals, Inc. (ELTP)
| Market Cap | 41.87M |
| Revenue (ttm) | 24.90M |
| Net Income (ttm) | 6.40M |
| Shares Out | 1.01B |
| EPS (ttm) | 0.01 |
| PE Ratio | 7.17 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 427,578 |
| Open | 0.0403 |
| Previous Close | 0.0400 |
| Day's Range | 0.0361 - 0.0430 |
| 52-Week Range | 0.0400 - 0.0900 |
| Beta | 0.77 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | Nov 15, 2021 |
About ELTP
Elite Pharmaceuticals, Inc. engages in the research, development, manufacture, and licensing of proprietary orally administered controlled-release drug delivery systems and products. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Hydromorphone HCl 8mg tablets fo...
Financial Performance
Financial StatementsNews
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2022 Ended June 30, 2021 a...
Conference Call Scheduled for Tuesday, August 17 at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / August 16, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company”) (OTCQB:ELTP), a specialty pharmaceu...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2022 Financ...
Financials for First Quarter Fiscal Year 2022 Ended June 30, 2021 will be released August 16, 2021 NORTHVALE, NJ / ACCESSWIRE / August 10, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (...
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2021 and Provides Conferenc...
Conference Call Scheduled for Tuesday, June 15 at 11:30 AM EDT NORTHVALE, NJ / ACCESSWIRE / June 14, 2021 / Elite Pharmaceuticals, Inc. ('Elite' or the "Company')(OTCBB:ELTP), a specialty pharmaceutical...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Year-End Financial Result...
Financials for Fiscal Year Ended March 31, 2021 will be released June 14, 2021 NORTHVALE, NJ / ACCESSWIRE / June 8, 2021 / Elite Pharmaceuticals, Inc. ('Elite' or the "Company') (OTCBB:ELTP), a specialt...
Elite Pharmaceuticals Enters into an Exclusive Distribution Agreement with Prasco, LLC and Announces Commercial Launc...
NORTHVALE, NJ / ACCESSWIRE / May 4, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today that its distribution and marketing partner Prasco, LLC ("Prasco"), has lau...
Elite Pharmaceuticals, Inc. Names Marc Bregman as Chief Financial Officer
NORTHVALE, NJ / ACCESSWIRE / April 29, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products,...
Elite Pharmaceuticals, Inc. Appoints Dr. Jason M. LePree as Vice President of Scientific Affairs
NORTHVALE, NJ / ACCESSWIRE / January 5, 2021 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products...